Migraine Clinical Trial
Official title:
Efficacy of Manual Therapy for the Treatment of Chronic Migraine.
Introduction According to the World Health Organization (WHO) at least 47% of adults have
suffered from headache in the last year. The headache is not only painful but also disabling,
it can be accompanied by social and personal problems, with a decrease in the quality of life
and with economic losses. Migraine affects a large number of people and, if the predisposing
factors are not controlled, it can become chronic. Once the chronification point of migraine
has arrived, it seriously affects the quality of life of people, both in the workplace,
social and leisure.
objective Perform the application of a manual therapy treatment based on protocols that
include techniques already proven to improve different areas of impact in patients with
migraine. To evaluate various aspects, we will include the intensity of pain, the frequency
of episodes, anxiety and depression, quality of life, etc ... and the limitations or
disability that it produces.
Material and methods This is a prospective, single-blind, randomized study with patients
diagnosed with migraine. The sample will be distributed in 4 groups: a) experimental group
that will receive combined treatment of soft tissues with techniques evidenced independently;
b) Group that will receive independent structural techniques; c) the group that will receive
the set of protocols a and b; d) and the placebo control group.
Evaluation An initial assessment will be carried out, another at the end of the treatment and
another follow-up one month after the end of the treatment. In addition, the evaluation will
include the following instruments: the HDI scale (Headache Disability Inventory), the MIDAS
scale (Migraine Disability Assessment Scale), the SF-36 Questionnaire, the EVA Scale
(Visual-Analogue Scale), the HIT-6 Questionnaire, the BDI Questionnaire (Beck Inventory
Depression), the STAI Questionnaire (The State-Trait Anxiety Inventory), the change perceived
after the treatment and medication intake.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
| Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
| Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
| Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
| Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
| Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
| Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
| Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
| Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
| Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
| Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
| Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
| Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
| Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
| Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
| Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
| Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
| Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
| Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
| Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |